A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine-derived membrane material in?patients with venous leg ulcers

详细信息    查看全文

• 作者：Teresa J. Kelechi ; PhD ; RN^a ; ^{kelechtj@musc.edu} ; Martina Mueller ; PhD^a ; Cheryl S. Hankin ; PhD^b ; Amy Bronstone ; PhD^b ; John Samies ; MD^c ; Phyllis A. Bonham ; PhD ; RN^a
• 关键词：membrane ; poly-N-acetyl glucosamine ; therapy ; venous leg ulcer ; wound healing
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2012
• 出版时间：June, 2012
• 年：2012
• 卷：66
• 期：6
• 页码：e209-e215
• 全文大小：545 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background

Standard care for venous leg ulcers (VLUs) has remained unchanged over several decades despite high rates of initial treatment failure and ulcer recurrence.

Objective

We sought to evaluate the efficacy, safety, and tolerability of an advanced, poly-N-acetyl glucosamine (pGlcNAc), nanofiber-derived, wound-healing technology among patients with VLUs (Talymed, Marine Polymer Technologies Inc, Danvers, MA).

Methods

In this randomized, investigator-blinded, parallel-group, controlled study, eligible patients were randomized to treatment with standard care plus pGlcNAc (applied only once, every other week, or every 3 weeks) or to standard care alone. The primary end point was the proportion of patients with complete wound healing at week 20 in the intent-to-treat population (all randomized subjects), with last observation carried forward.

Results

Among 82 randomized patients, 71 completed the study with 7 lost to follow-up and 4 discontinued because of systemic infection. There were no significant group differences with regard to baseline demographic, illness, and VLU characteristics. At 20 weeks, the proportion of patients with completely healed VLUs was 45.0 % (n?= 9 of 20), 86.4 % (n?= 19 of 22), and 65.0 % (n?= 13 of 20) for groups receiving standard care plus pGlcNAc only once, every other week, and every 3 weeks, respectively, versus 45.0 % (n?= 9 of 20) for those receiving standard care alone (P < .01 for pGlcNAc every other week vs standard care). The novel pGlcNAc advanced wound-healing technology was well tolerated and safe.

Limitations

Limitations were small sample size and patients unblinded to treatment allocation.

Conclusion

These pilot study results suggest that the pGlcNAc advanced wound-healing technology is well tolerated and effective.